Therapeutic Asset Ratings

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Liraglutide Inherited Lipid Metabolism Disorder	RenJi Hospital	P4	BB (69)
Liraglutide Obesity Disorder	Ali Aminian	P4	BB (69)
Loratadine Fabry Disease	Sanofi	P4	BB (69)
Lorazepam Schizoaffective Disorder	Temple University	P4	BB (69)
Lurasidone Bipolar Disorder	George West Mental Health Foundation d/b/a Skyland Trail	P4	BB (69)
Lurasidone Psychotic Disorder	George West Mental Health Foundation d/b/a Skyland Trail	P4	BB (69)
Mannitol Cystic Fibrosis	University of North Carolina, Chapel Hill	P4	BB (69)
Melatonin Circadian Rhythm Sleep Disorder	Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health	P4	BB (69)
Mexidol Ischemic Stroke	Pharmasoft	P4	BB (69)
Midazolam Anxiety Disorder	Theresa Jacob, PhD, MPH	P4	BB (69)
Mirabegron Asthma	Kafrelsheikh University	P4	BB (69)
Misoprostol Dystocia	University of Texas at Austin	P4	BB (69)
Montelukast Fabry Disease	Sanofi	P4	BB (69)
Naltrexone Obesity Disorder	Yale University	P4	BB (69)
Naltrexone Schizoaffective Disorder	Mayo Clinic	P4	BB (69)
Naproxen Chronic Pain Syndrome	Endeavor Health	P4	BB (69)
Nebivolol Hypertensive Disorder	Kafrelsheikh University	P4	BB (69)
Nepenthe Morbid Obesity	Kirsehir Ahi Evran Universitesi	P4	BB (69)
Nepenthe Substance-Related Disorder	Samsun University	P4	BB (69)
Nepenthe Sickle Cell Disease	Oman Medical Speciality Board	P4	BB (69)
Nicardipine Malignant Hypertension	Haseki Training and Research Hospital	P4	BB (69)
Nivestim Plasma Cell Myeloma	Janssen Research & Development, LLC	P4	BB (69)
Nivolumab Lung Cancer	University of Chicago	P4	BB (69)
Nivolumab Melanoma	Bristol-Myers Squibb	P4	BB (69)
Nivolumab Renal Cell Carcinoma	Fred Hutchinson Cancer Center	P4	BB (69)

Showing 1751 to 1775 of 42,327 assets

PreviousPage 71 of 1694Next